













Article

Clinical Heterogeneity and Different Phenotypes in Patients with *SETD2* Variants: 18 New Patients and Review of the Literature

Alejandro Parra ^{1,2,3} , Rachel Rabin ⁴ , John Pappas ^{4,5} , Patricia Pascual ^{1,2,3}, Mario Cazalla ², Pedro Arias ^{1,2,3}, Natalia Gallego-Zazo ^{1,2,3} , Alfredo Santana ⁶, Ignacio Arroyo ⁷, Mercè Artigas ⁸, Harry Pachajoa ⁹, Yasemin Alanay ^{10,11} , Ozlem Akgun-Dogan ^{10,11} , Lyse Ruaud ^{12,13} , Nathalie Couque ^{12,14} , Jonathan Levy ^{12,14}, Gloria Liliana Porras-Hurtado ¹⁵ , Fernando Santos-Simarro ¹⁶, Maria Juliana Ballesta-Martinez ^{17,18} , Encarna Guillén-Navarro ^{1,18}, Hugo Muñoz-Hernández ¹⁹, Julián Nevado ^{1,2,3}, Spanish OverGrowth Registry Initiative ^{20,†}, Jair Tenorio-Castano ^{1,2,3}  and Pablo Lapunzina ^{1,2,3,*} 

- ¹ CIBERER, Centro de Investigación Biomédica en Red de Enfermedades Raras, 28046 Madrid, Spain; alejandro.parra.externo@salud.madrid.org (A.P.); patripascual0@gmail.com (P.P.); palajara@gmail.com (P.A.); nataliagallegozazo@gmail.com (N.G.-Z.); guillen.encarna@gmail.com (E.G.-N.); jnevadobl@gmail.com (J.N.); jairantonio.tenorio@gmail.com (J.T.-C.)
- ² INGEMM-Idipaz, Institute of Medical and Molecular Genetics, 28046 Madrid, Spain; mario.cazalla16@gmail.com
- ³ ITHACA, European Reference Network, Hospital Universitario La Paz, 28046 Madrid, Spain
- ⁴ Clinical Genetic Services, Department of Pediatrics, NYU School of Medicine, New York, NY 10016, USA; rachel.rabin@nyulangone.org (R.R.); john.pappas@nyulangone.org (J.P.)
- ⁵ Clinical Genetics, NYU Orthopedic Hospital, New York, NY 10010, USA
- ⁶ Clinical Genetics Unit, Complejo Hospitalario Universitario Insular-Materno Infantil de Las Palmas de Gran Canaria, 35016 Las Palmas de Gran Canaria, Spain; consultageneticasantana@gmail.com
- ⁷ Pediatrics Department, San Pedro de Alcántara Hospital, 10003 Cáceres, Spain; ignacio.arroyo@salud-juntaex.es
- ⁸ Genetics Unit, Hospital de Navarra, 31008 Pamplona, Spain; merce.artigas.lopez@navarra.es
- ⁹ Fundación Valle del Lili, Universidad Icesi, 760032 Cali, Colombia; hmpachajoa@icesi.edu.co
- ¹⁰ Division of Pediatric Genetics, Department of Pediatrics, Faculty of Medicine, Acibadem Mehmet Ali Aydinlar University, Istanbul 34752, Turkey; yasemin.alanay@acibadem.edu.tr (Y.A.); ozlem.dogan@acibadem.edu.tr (O.A.-D.)
- ¹¹ Rare Diseases and Orphan Drugs Application and Research Center (ACURARE), Acibadem Mehmet Ali Aydinlar University, Istanbul 34752, Turkey
- ¹² Department of Genetics, APHP-Robert Debré University Hospital, 75019 Paris, France; lyse.ruaud@aphp.fr (L.R.); nathalie.couque@aphp.fr (N.C.); jonathan.levy@aphp.fr (J.L.)
- ¹³ INSERM UMR1141, Neurodiderot, University of Paris Cité, 75019 Paris, France
- ¹⁴ Laboratoire de Biologie Médicale Multisites Sequoia-FMG2025, 75014 Paris, France
- ¹⁵ Línea de Investigación de Anomalías Congénitas y Enfermedades Huérfanas-Comfamiliar, Risaralda, Colombia; glolipo@utp.edu.co
- ¹⁶ Unidad de Diagnóstico Molecular y Genética Clínica, Hospital Universitario Son Espases, Idisba, 07120 Palma de Mallorca, Spain; fsantossimarro@gmail.com
- ¹⁷ Sección de Genética Médica, Hospital Clínico Universitario Virgen de la Arrixaca, 30120 Murcia, Spain; mjballesta@ucam.edu
- ¹⁸ Instituto Murciano de Investigación Biosanitaria (IMIB), 30120 Murcia, Spain
- ¹⁹ Department of Biology, Institute of Molecular Biology and Biophysics, ETH Zurich, 8092 Zurich, Switzerland; hugo.munoz@mol.biol.ethz.ch
- ²⁰ Spanish OverGrowth Registry Initiative, La Paz University Hospital, 28046 Madrid, Spain; thesoygriconsortium@gmail.com
- * Correspondence: plapunzina@ciberer.es; Tel.: +34-91-727-72-17; Fax: +34-91-207-10-40
- † See acknowledgements for Spanish OverGrowth Registry Initiative.



Citation: Parra, A.; Rabin, R.; Pappas, J.; Pascual, P.; Cazalla, M.; Arias, P.; Gallego-Zazo, N.; Santana, A.; Arroyo, I.; Artigas, M.; et al. Clinical Heterogeneity and Different Phenotypes in Patients with *SETD2* Variants: 18 New Patients and Review of the Literature. *Genes* **2023**, *14*, 1179. <https://doi.org/10.3390/genes14061179>

Academic Editor: Xingguang Luo

Received: 11 May 2023

Revised: 25 May 2023

Accepted: 26 May 2023

Published: 29 May 2023



Copyright: © 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

Abstract: *SETD2* belongs to the family of histone methyltransferase proteins and has been associated with three nosologically distinct entities with different clinical and molecular features: Luscan–Lumish syndrome (LLS), intellectual developmental disorder, autosomal dominant 70 (MRD70), and Rabin–Pappas syndrome (RAPAS). LLS [MIM #616831] is an overgrowth disorder with multisystem

involvement including intellectual disability, speech delay, autism spectrum disorder (ASD), macrocephaly, tall stature, and motor delay. RAPAS [MIM #6201551] is a recently reported multisystemic disorder characterized by severely impaired global and intellectual development, hypotonia, feeding difficulties with failure to thrive, microcephaly, and dysmorphic facial features. Other neurologic findings may include seizures, hearing loss, ophthalmologic defects, and brain imaging abnormalities. There is variable involvement of other organ systems, including skeletal, genitourinary, cardiac, and potentially endocrine. Three patients who carried the missense variant p.Arg1740Gln in *SETD2* were reported with a moderately impaired intellectual disability, speech difficulties, and behavioral abnormalities. More variable findings included hypotonia and dysmorphic features. Due to the differences with the two previous phenotypes, this association was then named intellectual developmental disorder, autosomal dominant 70 [MIM 620157]. These three disorders seem to be allelic and are caused either by loss-of-function, gain-of-function, or missense variants in the *SETD2* gene. Here we describe 18 new patients with variants in *SETD2*, most of them with the LLS phenotype, and reviewed 33 additional patients with variants in *SETD2* that have been previously reported in the scientific literature. This article offers an expansion of the number of reported individuals with LLS and highlights the clinical features and the similarities and differences among the three phenotypes associated with *SETD2*.

Keywords: *SETD2*; Luscan–Lumish syndrome; Rabin–Pappas syndrome; intellectual developmental disorder; autosomal dominant 70; overgrowth; intellectual disability; autism spectrum disorder; MRD70; LLS; RAPAS

1. Introduction

Overgrowth syndromes (OGS) comprise a heterogeneous group of disorders whose main characteristic is that either the weight, height, or head circumference, (often also occurring together) are above the 97th centile or 2–3 standard deviations (SD) above the mean for age, gender, and ethnic group [1]. Most of the OGS are associated with other clinical features that sometimes overlap between them, making the clinical diagnosis a challenge for both pediatricians and geneticists.

Luscan–Lumish syndrome (LLS) [MIM 616831] is an infrequent overgrowth disorder [2]. The main clinical features of this condition include macrocephaly, tall stature, intellectual disability, speech delay, autism spectrum disorder (ASD), and motor delay [3]. In 2020, Rabin et al. [4] described a series of 12 patients associated with a missense variant at codon 1740 of the *SETD2* gene. Patients mostly had microcephaly, intellectual disability, and multiple congenital abnormalities, such as congenital heart defects, abnormality of the skeletal system, and/or abnormality of the genitourinary system. The phenotypic association was named RAPAS [MIM 6201551], and all of these patients carried the same de novo missense variant, p.Arg1740Trp. The same authors also described three patients who carried another missense variant at the same amino acid position, p.Arg1740Gln in the *SETD2* gene. This variant was present in patients with a different phenotype compared to those with RAPAS, including mild global developmental delay, moderately impaired intellectual disability with speech difficulties, and behavioral abnormalities. More variable findings included hypotonia and dysmorphic features. This association was then named the intellectual developmental disorder, autosomal dominant 70 (MRD70) [MIM 620157]. The fact that these phenotypes were different to the classic LSS could be explained by a possible gain-of-function mechanism, or an effect in the epigenetic regulation of this gene [4].

LLS, RAPAS, and MRD70 are caused by heterozygous variants in the set domain-containing protein 2 (*SETD2*) gene located on chromosome 3p21.31. *SETD2* encodes a protein belonging to the methyltransferase family of proteins, which are involved in histone regulation, playing an important role in gene expression regulation [5]. *SETD2* is also involved in other biological processes, such as DNA damage repair and DNA replication.

Its main function is the trimethylation of lysine 36 on histone H3 (H3K36me3) [6]. Moreover, SETD2 methylates α -tubulin at lysine 40 during mitosis and cytokinesis, participating in the maintenance of genomic stability through its dual-function methyltransferase for chromatin and cytoskeleton [7]. Other genes belonging to the histone methyltransferase family have also been associated with overgrowth disorders (i.e., *DNMT3A* and *BRWD3*) [8,9].

As many other genes that are involved in overgrowth disorders, *SETD2* is associated with several neoplastic processes at the somatic level. *SETD2* is absent or reduced in several cancers, supporting a tumor suppressive role of the protein [10]. In addition, somatic variants in *SETD2* have been found in many different cancers such as breast cancer, leukemia, and renal neoplasia [11,12].

Since the first detection of variants in *SETD2* as causative of ASD and a neurodevelopmental disorder [13,14], and the establishment of these variants as responsible for LLS, RAPAS, and MRD70 [2,4,15], only 33 patients have been reported to date, to the best of our knowledge. Most of these patients have been diagnosed by massive, paralleled sequencing technologies or NGS. Reported pathogenic or likely pathogenic variants in LLS, RAPAS and MRD70 comprise missense, nonsense, and frameshift variants in *SETD2*. In families in which segregation analysis was available, it was confirmed that most of the variants were *de novo*, and only in two patients was a vertical transmission reported [13].

Herein, we report 18 additional patients with variants in *SETD2* and a review of the clinical features found in LLS, RAPAS, and MDR70 patients from our cohort, and from all the individuals reported so far.

2. Material and Methods

2.1. Patients

Patients were selected from the Spanish Overgrowth Syndromes Registry Initiative (SOGRI), which comprises more than 2200 individuals and relatives with overgrowth disorders. This study was approved by the ethical committee of the Hospital Universitario La Paz (CEIm PI-446), and informed consent was obtained from all patients and/or their parents.

In addition to the SOGRI patients, a review of all previously reported patients in the scientific literature was made, and the phenotypes of these individuals were compared with those of the SOGRI described in this report. Additional patients were collected with collaborative support tools, including GeneMatcher [16].

2.2. Genetic Analysis

All patients from the Hospital Universitario La Paz were analyzed by a custom NGS panel using a Roche SeqCap EZ Kit (Roche, Basel, Switzerland) capture kit, and sequencing was performed with NextSeq500 technology (Illumina, CA, USA). A customized in-house bioinformatic pipeline was developed to analyze the raw data. This pipeline consisted of base calling, alignment, local realignment, duplicate removal, quality recalibration, data merging, variant detection, genotyping, and annotation. Quality control checkpoints were undertaken at numerous points to ensure the quality and integrity of the data, and as a result, the BAM and VCF files were obtained. Candidate variants that were obtained following a custom prioritization pipeline were validated by Sanger sequencing according to the standard procedures, and electropherograms were analyzed with Sequencher v4.1.4 (Genecodes, MI, USA). Patients from the other centers were analyzed either by their own NGS panels or with whole exome sequencing. Variant classification was made according to the qualitative American College of Medical Genetics and Genomics (ACMG) guidelines [17].

2.3. Protein Structural Analysis

The protein structure of wild type SETD2 1400–1800 and variants p.Glu1718Lys, p.Arg1740Trp, and p.Arg1740Gln were predicted using the Alphafold 2.1.1 neural net-

work [18,19] and database of the scientific computing of ETH Zürich. The visualization was performed using UCSF ChimeraX [20,21].

3. Results

3.1. Molecular Results

We analyzed *SETD2* variants in 18 novel patients by NGS and identified 15 different genetic variants (four of them presented the same variant). Detailed information of the detected variants is shown in Table 1. None of the variants except for the p.Gln7Ter variant were previously reported in the literature. Nine out of the fifteen variants (60%) were absent in the pseudo-control population databases (gnomAD exomes, gnomAD genomes, Kaviar, 1000G, ESP, Beacon, and Bravo, respectively). The other six variants were found to have an extremely low population frequency: p.His866_Tyr871del: 0.00000657, p.Gln7Ter: 0.000244, p.Asp2100Gly: 0.00000657, and p.Asn1257Tyr: 0.00000657, respectively (data source: gnomAD genomes version 3.1.2). We also reviewed patients with *SETD2* variants previously reported in the literature, leading to 51 individuals being identified with variants in this gene reported so far. All *SETD2* variants reported are displayed in Figure 1 and listed in Table 1. To sum up, thirty-four genetic variants have been detected in this cohort of patients, comprising sixteen missense, nine frameshift, seven nonsense, one in-frame deletion, and one splicing variant, respectively. According to the guidelines of the American College of Medical Genetics (ACMG) [17], 15 variants were classified as pathogenic, 5 variants were classified as likely pathogenic, and the other 14 were classified as variants of unknown significance (VUS).




Figure 1. Variants identified in *SETD2*. (A) Exons and introns that conform to the *SETD2* gene according to the transcript number NM_014159.7. (B) The *SETD2* protein, which is organized into different domains: AWS, associated with the SET domain; SET, Lysine N-methyltransferase domain; PS, post-SET domain; LCR, low charge region; and WW, WW domain. Red dots, variants associated with LLS; blue dots, variants associated with RAPAS; and green dots, variant associated with MRD70.

Table 1. Variants detected in the *SETD2* gene. Abbreviations: N/E, not evaluated; VUS, variant of uncertain significance; P, pathogenic; LP, likely pathogenic; LLS, Luscan–Lumish syndrome; RAPAS, Rabin–Pappas syndrome; and MRD70, intellectual developmental disorder, autosomal dominant 70. * Current age in years; † Allele frequency was estimated from several population pseudo-control databases: gnomAD genomes (v3.0), gnomAD exomes (v3.1), Kaviar (version 160204-Public), Beacon (v2.0), 1000 G, Phase III, and Bravo (TOVMed Freeze 8); § ACMG, American College of Medical Genetics.

Patient	Age *	Sex	Genomic Coordinate (hg38)	cDNA and Protein Location (NM_014159.7)	Exon/Intron	Mutation Type	Inheritance	Population Frequency †	CADD Score	ACMG Prediction §	Phenotype	Reference
1	14	Male	chr3:47116623	c.4586G>C (p.Cys1529Ser)	4	Missense	De novo	-	33	LP	LLS	This study
2	13	Male	chr3:47122021	c.2598_2615del (p.His866_Tyr871del)	3	In-frame deletion	Inherited from father	0.00000657	-	VUS	LLS	This study
3	17	Male	chr3:47163906	c.19C>T (p.Gln7Ter)	1	Nonsense	N/E	0.000244	35	VUS	LLS	This study
4	16	Male	chr3:47163906	c.19C>T (p.Gln7Ter)	1	Nonsense	N/E	0.000244	35	VUS	LLS	This study
5	21	Female	chr3:47163906	c.19C>T (p.Gln7Ter)	1	Nonsense	Inherited from mother	0.000244	35	VUS	LLS	This study
6	53	Female	chr3:47163906	c.19C>T (p.Gln7Ter)	1	Nonsense	N/E	0.000244	35	VUS	LLS	This study
7	26	Female	chr3:47056863	c.6921dupT (p.Val2308CysfsTer61)	15	Frameshift	N/E	-	-	P	LLS	This study
8	29	Male	chr3:47116749	c.4457_4460del (p.Lys1486ArgfsTer28)	4	Frameshift	N/E	-	-	P	LLS	This study
9	9	Female	chr3:47057485	c.6299A>G (p.Asp2100Gly)	15	Missense	N/E	0.00000657	28.1	VUS	LLS	This study
10	8	Male	chr3:47121949	c.2687C>T (p.Thr896Ile)	3	Missense	De novo	-	16.11	VUS	LLS	This study
11	4	Female	chr3:47122915	c.1717_1720del (p.Phe573ValfsTer5)	3	Frameshift	De novo	-	-	P	LLS	This study
12	5	Female	chr3:47121197	c.3439C>T (p.Gln1147Ter)	3	Nonsense	De novo	-	36	P	LLS	This study
13	6	Female	chr3:47088238	c.5152G>A (p.Glu1718Lys)	10	Missense	De novo	-	28.5	VUS	RAPAS	This study
14	15	Male	chr3:47120867	c.3769A>T (p.Asn1257Tyr)	3	Missense	Inherited from father	0.00000657	23.9	VUS	LLS	This study
15	13	Male	chr3:47120672	c.3964C>T (p.Arg1322Ter)	3	Nonsense	De novo	-	36	P	LLS	This study
16	11	Male	chr3:47124539	c.97G>A (p.Glu33Lys)	3	Missense	Inherited from mother	-	25.9	VUS	LLS	This study
17	13	Male	chr3:47017164	c.7624G>A (p.Glu2542Lys)	21	Missense	De novo	-	27.5	VUS	LLS	This study

Table 1. Cont.

Patient	Age *	Sex	Genomic Coordinate (hg38)	cDNA and Protein Location (NM_014159.7)	Exon/Intron	Mutation Type	Inheritance	Population Frequency †	CADD Score	ACMG Prediction §	Phenotype	Reference
18	4	Female	chr3:47057031	c.6753C>G (p.Asp2251Glu)	15	Missense	De novo	-	15.7	VUS	RAPAS	This study
19	15	Male	chr3:47123454	c.1182T>A (p.Cys394Ter)	3	Nonsense	Inherited from father	-	35	LP	LLS	[13]
20	15	Male	chr3:47163906	c.19C>T (p.Gln7Ter)	1	Nonsense	Inherited from mother	0.000244	35	VUS	LLS	[13]
21	26	Male	chr3:47124515	c.121A>T (p.Ile41Phe)	3	Missense	De novo	-	17.7	VUS	LLS	[13]
22	26	Female	chr3:47057443	c.6341delA (p.Asn2114IlefsTer33)	15	Frameshift	De novo	-	-	P	LLS	[13]
23	26	Female	chr3:47123816	c.820C>T (p.Gln274Ter)	3	Nonsense	N/E	-	34	P	LLS	[2]
24	29	Male	chr3:47084336	c.5444T>G (p.Leu1815Trp)	12	Missense	De novo	-	28	LP	LLS	[2]
25	24	Female	chr3:47122608	c.2028delT (p.Pro677LeufsTer19)	3	Frameshift	De novo	-	-	P	LLS	[15]
26	18	Male	chr3:47086306	c.5285_5286delAC (p.His1762LeufsTer26)	11	Frameshift	De novo	-	-	P	LLS	[22]
27	9	Male	chr3:47122969	c.1647_1667delinsAC (p.Asp549GlufsTer24)	3	Frameshift	De novo	-	-	P	LLS	[23]
28	27	Female	chr3:47057009	c.6775delG (p.Val2259CysfsTer50)	15	Frameshift	De novo	-	-	P	LLS	[23]
29	6	Female	chr3:47120360	c.4276A>T (p.Lys1426Ter)	3	Nonsense	N/E	-	37	P	LLS	[24]
30	8	Female	chr3:47103389	c.4874G>A (p.Arg1625His)	7	Missense	N/E	-	29	VUS	LLS	[24]
31	11	Male	chr3:47057313	c.6471T>A (p.Tyr2157Ter)	15	Nonsense	De novo	-	36	P	LLS	[24]
32	13	Male	chr3:47101476	c.4997A>G (p.Tyr1666Cys)	8	Missense	De novo	-	31	LP	LLS	[24]
33	22	Male	chr3:47124400	c.236T>A (p.Leu79His)	3	Missense	De novo	-	25.1	VUS	LLS	[25]
34	6	Male	chr3:47113875	c.4715+1G>A	intron 5	Splicing	De novo	-	34	P	LLS	[3]
35	6	Female	chr3:47121451	c.3185C>T (p.Pro1062Leu)	3	Missense	De novo	-	26.2	VUS	LLS	[3]
36–47	-	-	chr3:47088172	c.5218C>T (p.Arg1740Trp)	10	Missense	De novo	-	32	LP	RAPAS	[4]
48–50	-	-	chr3:47088171	c.5219G>A (p.Arg1740Gln)	10	Missense	De novo	-	28.5	VUS	MRD70	[4]
51	3	M	chr3:47083945	c.5835_5836insAGAA (p.Ala1946ArgfsTer3)	12	Frameshift	De novo	-	-	P	LLS	[26]

3.2. Clinical Features of Reported Patients

Clinical features of the patients reported herein are listed in Table 2, and pictures of several of these patients are shown in Figure 2. We also reviewed the clinical information of the 18 novel and those previously published patients with confirmed genetic variants in *SETD2* (n = 51). We separated these patients according to their phenotypes in three groups: Group 1—thirty-four patients with LLS; Group 2—fourteen patients with RAPAS, and Group 3—three patients with MRD70. Table 3 shows the frequency of clinical features in the three different groups of patients with variants in the *SETD2* gene. Figure 3 shows a distribution of the most relevant clinical features of each disorder. Intellectual disability was the most common clinical feature found among the three groups. Macrocephaly (67%), overgrowth (50%), and autism (50%) were identified as the clinical features with the highest frequency in patients with the LLS phenotype (group 1). Other common clinical features were speech delay (44.1%), developmental delay (38.2%), prominent forehead (32.4%), obesity (32.4%), motor delay (32.4%), and tall stature (29.4%). In patients with RAPAS, intellectual disability, microcephaly, abnormality of the skeletal system, absent speech, motor delay, developmental delay, and hypotonia were found in all patients. Hypertelorism, cerebellar hypoplasia, congenital heart defects, abnormality of the genitourinary system, failure to thrive in infancy, feeding difficulties, and micrognathia were observed in 12 patients (85.7%). Although the three patients with MRD70 share a few clinical features with patients of the group 2 (RAPAS phenotype), individuals with RAPAS are severely affected with multiple congenital anomalies and a profound intellectual disability. Mild intellectual disability (100%), abnormality of the skeletal system (66.6%), hypotonia (66.6%), and retrognathia (66.6%) were the most common clinical features identified in MRD70 individuals.

Table 2. Clinical features of reported patients. Detailed description of the clinical features at its frequency in the entire set of patients analyzed. Clinical features are standardized according to the human phenotype ontology (HPO).

Clinical Features	P1	P2	P3	P4	P5	P6	P7	P8	P9	P10	P11	P12	P13	P14	P15	P16	P17	P18	No. Patients	% Patients
HP:0000256 Macrocephaly																			11	61.1
HP:0001249 Intellectual disability																			9	50.0
HP:0001548 Overgrowth																			8	44.4
HP:0001263 Developmental delay																			8	44.4
HP:0001270 Motor delay																			8	44.4
HP:0011220 Prominent forehead																			7	38.9
HP:0000750 Speech delay																			7	38.9
HP:0000729 Autism spectrum disorder																			6	33.3
HP:0000337 Broad forehead																			6	33.3
HP:0001252 Hypotonia																			6	33.3
HP:0000348 Scoliosis																			5	27.8
HP:0001627 Congenital heart defect																			5	27.8
HP:0000483 Astigmatism																			4	22.2
HP:0000348 High forehead																			4	22.2
HP:0001513 Obesity																			4	22.2
HP:0000098 Tall stature																			4	22.2
HP:0000924 Abnormality of the skeletal system																			4	22.2
HP:0009890 High anterior hairline																			4	22.2
HP:0000739 Anxiety																			3	16.7
HP:0007018 Attention deficit hyperactivity disorder																			3	16.7
HP:0000708 Behavioral abnormality																			3	16.7

Table 2. Cont.

Clinical Features		P1	P2	P3	P4	P5	P6	P7	P8	P9	P10	P11	P12	P13	P14	P15	P16	P17	P18	No. Patients	% Patients	
HP:0002007	Frontal bossing																			3	16.7	
HP:0001999	Abnormal facial shape																				2	11.1
HP:0000077	Abnormality of the kidney																				2	11.1
HP:0001176	Long/Large hands																				2	11.1
HP:0003764	Nevus																				2	11.1
HP:0000486	Strabismus																				2	11.1
HP:0000316	Hypertelorism																				2	11.1
HP:0000252	Microcephaly																				2	11.1
HP:0001250	Seizure																				2	11.1
HP:0410263	Brain imaging abnormality																				2	11.1
HP:0000119	Abnormality of genitourinary system																				1	5.6
HP:0005616	Advanced bone age																				1	5.6
HP:0002119	Ventriculomegaly																				1	5.6
HP:0011427	Enlarged cisterna magna																				1	5.6
HP:0001601	Laryngomalacia																				1	5.6
HP:0010535	Sleep apnea																				1	5.6
HP:0000278	Retrognathia																				1	5.6
HP:0000464	Abnormality of the neck																				1	5.6
HP:0007763	Retinal telangiectasia																				1	5.6



Figure 2. Facial dysmorphic features of several of the individuals reported herein. Patient 1 (A,B), patient 8 (C–F), patient 5 (G), patient 6 (H), patient 7 (I,J), patient 10 (K,L), patient 9 (M,N), patient 16 (O,P) and patient 18 (Q).

Table 3. Frequency of clinical features in the different groups of patients with variants in the *SETD2* gene. LLS, Luscan–Lumish syndrome; RAPAS, Rabin–Pappas syndrome; and MRD70, Intellectual developmental disorder, autosomal dominant 70.

HPO Terms Clinical Features	LLS Patients		RAPAS Patients		MRD70 Patients		
	No. Patients	% Patients	No. Patients	% Patients	No. Patients	% Patients	
HP:0000256	Macrocephaly	23	67.6	0	0	0	0
HP:0001548	Overgrowth	17	50.0	0	0	0	0
HP:0000729	Autism spectrum disorder	17	50.0	0	0	0	0
HP:0001249	Intellectual disability	16	47.1	14	100	3	100
HP:0000750	Speech delay	15	44.1	0	0	3	100
HP:0001263	Developmental delay	13	38.2	14	100	3	100
HP:0011220	Prominent forehead	11	32.4	1	7.1	0	0
HP:0001513	Obesity	11	32.4	0	0	0	0
HP:0001270	Motor delay	11	32.4	14	100	2	66.7
HP:0000098	Tall stature	10	29.4	0	0	0	0
HP:0007018	Attention deficit	9	26.5	0	0	0	0
	hyperactivity disorder						
HP:0000708	Behavioral abnormality	9	26.5	0	0	0	0
HP:0009890	High anterior hairline	8	23.5	1	7.1	0	0
HP:0000388	Otitis media	8	23.5	0	0	0	0
HP:0000337	Broad forehead	6	17.6	1	7.1	0	0
HP:0001833	Large feet	6	17.6	0	0.0	0	0
HP:0001252	Hypotonia	5	14.7	14	100	2	66.7
HP:0000483	Astigmatism	5	14.7	0	0	0	0
HP:0001176	Long/Large hands	5	14.7	0	0	0	0
HP:0000718	Aggressive behavior	5	14.7	0	0	0	0
HP:0000348	High forehead	5	14.7	0	0	0	0
HP:0000494	Downslanted palpebral	5	14.7	0	0	0	0
	fissures						
HP:0000316	Hypertelorism	4	11.8	12	85.7	0	0
HP:0002007	Frontal bossing	4	11.8	1	7.1	0	0
HP:0000278	Scoliosis	4	11.8	8	57.1	0	0
HP:0000307	Pointed chin	4	11.8	0	0	1	33.3
HP:0001627	Congenital heart defect	4	11.8	12	85.7	0	0
HP:0000739	Anxiety	4	11.8	0	0	0	0
HP:0003764	Nevus	4	11.8	0	0	0	0
HP:0000276	Long face	4	11.8	0	0	0	0
HP:0002719	Recurrent infections	4	11.8	2	14.3	0	0
HP:0001250	Seizures	3	8.8	8	57.1	0	0
HP:0000924	Abnormality of the skeletal	2	5.9	14	100	2	66.7
	system						
HP:0000272	Malar flattening	2	5.9	0	0	1	33.3
HP:0007360	Cerebellar hypoplasia	1	2.9	12	85.7	0	0
HP:0007370	Hypoplasia of the corpus	1	2.9	9	64.3	0	0
	callosum						
HP:0000405	Conductive hearing	1	2.9	7	50.0	0	0
	impairment						
HP:0001344	Absent speech	1	2.9	14	100	0	0
HP:0000252	Microcephaly	0	0	14	100	0	0
HP:0011968	Feeding difficulties	0	0	13	92.8	0	0
HP:0001531	Failure to thrive in infancy	0	0	12	85.7	0	0
HP:0000347	Micrognathia	0	0	12	85.7	0	0
HP:0000119	Abnormality of the	0	0	12	85.7	0	0
	genitourinary system						
HP:0002553	Highly arched eyebrow	0	0	11	78.6	0	0
HP:0000455	Broad nasal tip	0	0	9	64.3	1	33.3
HP:0002791	Hypoventilation	0	0	9	64.3	0	0
HP:0009765	Low-hanging columella	0	0	9	64.3	0	0
HP:0000431	Wide nasal bridge	0	0	9	64.3	0	0
HP:0007763	Retinal telangiectasia	0	0	9	64.3	0	0
HP:0002902	Hyponatremia	0	0	8	57.1	0	0
HP:0000327	Hypoplasia of the maxilla	0	0	8	57.1	0	0
HP:0012110	Hypoplasia of the pons	0	0	8	57.1	0	0
HP:0000629	Periorbital fullness	0	0	8	57.1	0	0
HP:0007763	Retinal telangiectasia	0	0	8	57.1	0	0
HP:0012745	Short palpebral fissure	0	0	8	57.1	0	0
HP:0000582	Upslanted palpebral	0	0	5	35.7	1	33.3
	fissures						
HP:0000278	Retrognathia	0	0	1	7.1	2	66.7




Figure 3. Venn diagram showing the most relevant clinical features of each *SETD2*- related disorder and their overlap between them. LLS, Luscan–Lumish syndrome; RAPAS, Rabin–Pappas syndrome; and MRD70, intellectual developmental disorder, autosomal dominant 70.

4. Discussion

SETD2 encodes a lysine methyltransferase protein which trimethylates lysine 36 of histone H3 (H3K36me3) and methylates α -tubulin at lysine 40 [6,7]. Histone methylation is critical for embryonic development, and its dysregulation can lead to abnormalities in body patterning and defects in specific organ development. Loss of *SETD2*, which has previously been assessed through *SETD2* conditional knockouts in mice, revealed that this gene is essential for proper cortical arealization and corticothalamic projection formation. In addition, these *SETD2* knockout mice also displayed defects in social interaction, motor learning, and spatial memory, resembling LLS patients [27]. Moreover, knockout of *SETD2* results in defects in neuronal morphology transition, and therefore, in radial migration transition [28].

Here, we report 18 new patients with heterozygous variants in *SETD2*. So far, 33 patients have been reported with *SETD2* variants [2–4,13,15,22–26]. Thus, this report reviewed and summarized the information of 51 patients and emphasized the clinical heterogeneity in individuals carrying these *SETD2* variants. Pathogenic or likely pathogenic variants in *SETD2* can result in three different phenotypes: LLS, RAPAS, and MRD70, depending on the position of the variant in the protein [4]. The 51 patients we evaluated in this study were separated according to their phenotype: 34 LLS patients, 14 RAPAS patients, and 3 MRD70 patients.

Sixteen out of the eighteen novel patients described here had a clinical presentation compatible with LLS. The two remaining patients (patients #13 and #18) showed clinical features consistent with RAPAS. No patients with the MRD70 phenotype were found in our series. The results of the clinical study of our cohort supported the fact that macrocephaly, overgrowth, intellectual disability, autism, and delayed speech are the clinical features more commonly observed in LLS patients. Macrocephaly was the clinical feature with the highest frequency in LLS patients; it occurred in 23/34 patients, and 18 out of these 23 patients presented likely gene-disrupting variants (LGD), frameshift, or nonsense variants. Macrocephaly, together with overgrowth occurred in 15/34 (44.1%) patients. As is

shown in Figure 2, LGD variants are not randomly distributed along the gene. It seems that there are two clusters of LGD variants, one between the codons 270 and 700 and the other one in the low charge region (LCR). Patients with LGD variants in these clusters tended to have more frequent macrocephaly, overgrowth, speech delay, autism, and developmental delays. In addition, a lack of LGD variants can be observed in the functional region of the protein (AWS-SET-PS domains). This may suggest that a highly deleterious effect on this region of the protein may produce an aberrant form incompatible with life development.

Patient 2 is a 13-years-old male with a head circumference >5SD. Gene panel sequencing enabled the detection of a heterozygous in-frame deletion variant c.2598_2615del (p.His866_Tyr871del) in *SETD2*. Genetic testing also detected a missense variant NM_000314.8:c.464A>G (p.Tyr155Cys) in *PTEN*. Both variants were inherited from the father, who presented with macrocephaly as well but with no other clinical features to resemble. Pathogenic variants in *PTEN* lead to the autosomal dominant disorder macrocephaly/autism syndrome [MIM #605309], among other overgrowth disorders and cancer processes at the somatic level. Patient 2 presented a very pronounced macrocephaly (>5SD). Both LLS due to *SETD2* and macrocephaly/autism syndrome due to *PTEN* pathogenic variants include macrocephaly as a common clinical feature. The head circumference measurement of this patient might be due to an additive effect of both genes. In fact, the additive effect of *PTEN* with other genes in several other malignancies has already been demonstrated [29].

Patients 3 to 6 and patient 20 all share the same nonsense variant NM_014159.7:c.19C>T (p.Gln7Ter) in *SETD2*. In patients 3 and 4, segregation analysis of the variant could not be performed, but vertical transmission of this variant was confirmed in patients 5 and 20. Both patients 5 and 20 inherited the variant from their mothers. The p.Gln7Ter variant results in a premature termination codon, which has been predicted to cause a truncation of the encoded protein, or the degradation of the transcript through the nonsense mediated decay (NMD) machinery. This variant is present in 40 alleles in gnomAD Exomes and gnomAD Genomes, with 39 of them belonging to the Latino subpopulation (with 0.000353 and 0.00229 allele frequencies in the Latino subpopulation in gnomAD Exomes and gnomAD Genomes, respectively). According to the guidelines of the ACMG, this variant has been classified as a variant of unknown significance (VUS). This variant is located in the first exon of the canonical transcript. However, for the rest of the transcripts, the variant is located within the 5'UTR region. Therefore, protein disruption could only take place in the canonical transcript. According to the GTex Portal, the canonical transcript is the second with the highest expression. Moreover, codon 12 of the canonical transcript is a methionine which, under the proper conditions, could act as a secondary translation initiator. Despite the fact that the five patients display several clinical features compatible with LLS, it seems that there is not enough evidence to classify the p.Gln7Ter variant as either pathogenic or likely pathogenic at this moment.

Patient 13 is a six year-old female who is heterozygous for the variant NM_014159.7:c.5152G>A (p.Glu1718Lys). She mainly presented with microcephaly, intellectual disability, developmental delay, motor delay, hypotonia, congenital heart defect, enlarged cisterna magna, and abnormality of the skeletal system (Table 2). She did not present clinical features common to other LLS patients. Despite the fact that she did not present the p.Arg1740Trp change that could point to RAPAS syndrome, microcephaly, intellectual disability, and abnormality of the skeletal system are clinical features present in all RAPAS patients. To date, the p.Arg1740Trp variant is the only one associated with RAPAS syndrome. The underlying mechanisms of this disorder are still unknown, though gain-of-function, effects on epigenetics regulation, or posttranslational modification of the cytoskeleton are putative suggested mechanisms [4]. Figure 4A,B shows a three-dimensional structure prediction of wild type SETD2. Under standard conditions, arginine 1740 is in an alpha helix, and interacts with the arginine 1744. At the same time, arginine 1744 has been predicted to be bonded to the glutamic acid 1718 by three hydrogen bonds. Figure 4C represents several three-dimensional structure predictions of SETD2 when the variants p.Arg1740Trp,

p.Arg1740Gln, and p.Glu1718Lys occur. For the variant p.Arg1740Trp, the introduction of a nonpolar aromatic residue into an alpha helix may lead to a considerable structural alteration of the protein and thus affect its function. Therefore, the specific change at this position may lead to the development of RAPAS syndrome. Strikingly, in the same amino acid, there is another change (p.Arg1740Gln) which results in a missense substitution from the arginine amino acid to a glutamine residue. This change has been predicted to exhibit a minor effect on the protein function compared to the p.Arg1740Trp and may be also correlated with the differential phenotype observed in MRD70. Another option is that RAPAS and MRD70 are the same entity with highly heterogeneous clinical manifestations. Figure 4C(i) shows a comparison between the three-dimensional structure predictions of the wild type codon 1718 (Glu) and the changed one (Lys) in patient #13. Under standard conditions, wild type glutamic acid is predicted to be bonded to the arginine 1744 by three hydrogen bonds. When the c.5152G>A occurs, this Glu1718 is changed to a Lys and consequently, these three hydrogen bonds seem to disappear. In addition, glutamic acid is a negatively charged amino acid, while lysine is a positively charged amino acid. All this could lead to an effect in the structure or electronic environment of this region of the protein. As arginine 1744 is located in close proximity to arginine 1740, the missense variant p.Glu1718Lys may result in a similar alteration than the p.Arg1740Trp. This might explain why Patient 13 displays a similar phenotype to RAPAS patients.




Figure 4. (A) Three-dimensional structure predictions of SETD2, from amino acid 1400 to 1800, based on NM_014159.7. Color key of predicted aligned error min = 20, ad max = 100. (B) Post_SET helical platform, showing the hydrogen bonds interactions occurring between the positions 1718-1740-1744 in purple. (C) Three-dimensional details of the variants (i) p.Glu1718Lys, (ii) p.Ar1740Trp, and (iii) p.Arg1740Gln, respectively.

Patient 18 is a four-year-old female with microcephaly, intellectual disability, hypotonia, ventriculomegaly, seizures, and abnormality of the skeletal system, among other clinical features. Her clinical presentation is compatible with RAPAS; however, similar to patient #13, she did not present the p.Arg1740Trp variant. In this patient, genetic testing revealed the missense variant NM_014159.7:c.6753C>G (p.Asp2251Glu). The functional interpretation of this finding remains inconclusive.

Although patient #13 and patient #18 have a consistent phenotype with RAPAS, they did not display the complete presentation of this syndrome, as neither of them had the characteristic brain abnormalities of RAPAS (cerebellar hypoplasia, hypoplasia of the pons, or hypoplasia of corpus callosum). To date, it seems that only patients with the variant p.Arg1740Trp in *SETD2* have the complete presentation of RAPAS.

In conclusion, we report 18 new patients with *SETD2* variants and review all the published patients to date raising a total of 51 patients described so far. Patients with *SETD2* variants are clinically heterogeneous and their clinical presentations seem to depend on the effect and/or the location of the variant among the protein. To date, pathogenic variants in *SETD2* are responsible for up to three different phenotypes. Loss-of-function variants located along almost the entire length of the gene lead to LLS, while missense variants at the specific position 1740 of the protein lead to at least two different phenotypes, named as RAPAS (p.Arg1740Trp) or MRD70 (p.Arg1740Gln). Strikingly, we report two patients with a change in different amino acid positions (p.Glu1718Lys and p.Asp2251Glu, respectively) with clinical presentations that are compatible with RAPAS, suggesting that other variants could lead to the same phenotype outside the amino acid position 1740. Our in silico protein model analysis revealed an interaction between amino acids 1744 and 1718, which can be associated with the distinctive phenotype in patients with variants at position 1740 of *SETD2*.

It is necessary to carry out further functional studies to understand the molecular mechanisms of these *SETD2* variants, and increase the number of patients assessed with variants in the *SETD2* gene to further define the phenotype splitting or lumping the nosology around this gene.

Author Contributions: Conceptualization, J.T.-C. and P.L.; Methodology, A.P., P.A., J.N., J.T.-C. and P.L.; Software, M.C. and H.M.-H.; Validation, A.P., P.P., P.A., N.G.-Z., J.N. and J.T.-C.; Formal analysis, A.P., J.T.-C. and P.L.; Investigation, A.P., R.R., J.P., P.P., N.G.-Z., J.N., J.T.-C. and P.L.; Resources, R.R., J.P., A.S., I.A., M.A., H.P., Y.A., O.A.-D., L.R., N.C., J.L., G.L.P.-H., F.S.-S., M.J.B.-M., E.G.-N. and Spanish OverGrowth Registry Initiative; Data curation, A.P., R.R., M.C., J.T.-C. and P.L.; Writing—original draft, A.P.; Writing—review and editing, A.P., R.R., J.P., J.T.-C. and P.L.; Visualization, A.P., P.P., H.M.-H. and J.T.-C.; Supervision, J.T.-C. and P.L.; Project administration, J.T.-C. and P.L.; Funding acquisition, P.L. All authors have read and agreed to the published version of the manuscript.

Funding: This research was funded by the FIS PI20/01053, from the ISCIII with funding from FEDER, Europe; by PMP21/00063 from the ISCIII with funding from the FEDER, Europe and PMP22/00049 from the ISCIII with funding from the FEDER, Europe.

Institutional Review Board Statement: This study was conducted according to the guidelines of the Declaration of Helsinki and approved by the Institutional Review Board (or Ethics Committee) of the La Paz University Hospital (CEIm PI-446).

Informed Consent Statement: Informed consent was obtained from all participants involved in the study.

Data Availability Statement: Authors can confirm that all relevant data are included in the article.

Acknowledgments: We would like to thank all the families who were involved in this project, as well as the participants of the Spanish OverGrowth Registry Initiative (SOGRI) Consortium. The SOGRI (Spanish OverGrowth Registry Initiative) Consortium is comprised of the following researchers: Antonio Plasencia, Alberto L. Rosa, Aleixandre Blanquer, Alfredo Garcí'a-Alix, Alfredo Santana, Alicia Delicado, Almudena Alonso, Amaya Rodriguez, Amparo Sanchis, Ana Moreno, Ana Patiño García, Ana Vega, Analía Bredani, Andrea Paula Solari, Andrea Villavicencio, Angelina Acosta, Anibal Nieto, Anna María Cueto González, Antonio Baldellón, Antonio González Meneses,

Antonio Martínez Carrascal, Aranzazu Díaz de Bustamante, Arteché Ocasar, Blanca Gener, Blasco González, Boris Groisman, Bradford Coffee, Carlos Alcalde Martín, Carmen Aragon Fernández, Carmen Benito, Carmen Martín Seisdedos, Carmen Roche, Claudia Arberas, Claudia Perandones, Claudio Contessotto, Cristina Olivas, Daniel Armenta, Denise Cavalcanti, Dolores Elorza, Elena Zamora, Elisa Zambrano, Elisabeth Steichen, Enrique Caro Cruz, Enrique Galán Gómez, Enriqueta Román, Ernesto Goldschmidt, Esteban Marfil, Esther Gean, Eugenia Antolín, F. Javier Gascón Jiménez, Feliciano Ramos, Fermina López Grondona, Fernández Córdoba, Fernando Regla Vargas, Francisco Martínez, J. Miguel García Vegada, Giovannucci Uzielli, Gloria Gacio, Carmen González Armengod, Graciela Mercado, Hamilton Cassinelli, Ieda Orioli, Ignacio Arroyo, Ignacio Díez López, Ignacio Onsurbe Ramírez, Ignacio Pascual Castroviejo, Ignacio Pascual Pascual, Ignacio Vázquez Río, Inés Bueno, Isabel Espejo Portero, Isabel Lorda Sánchez, Jaime Sánchez del Pozo, Jaume Campistol, Javier Arcas, Javier Fernández, Javier García Planells, Javier López Pisón, Jesús Barreiro, Jesús del Valle Nuñez, María José Jiménez Liria, Joaquín Fernández Toral, Joaquín Ramírez, Jordi Rosell, Jorge Vilaplana, José Carlos Cabral de Almeida, José Ignacio Labarta, José L. Herranz, José Luis Fernández Luna, José Luis Fuster, José M. Díaz, Jose M. Gairi, José Miguel García Sagredo, Juan A. Piñero, Juan Carlos López Gutiérrez, Juan Manuel Fernández, Juan P. López Siguero, Juan Tovar, Judith Armstrong, Julián Lara, Leonor Arranz, Laura Rodríguez, Leandro Soriano, Liliana De Alba, Loreta Cimbaliestiene, Loreto Martorell, Luis González Gutiérrez Solana, Luis Pérez Jurado, M Asunción López Ariztegui, M. Antonia Molina, M. Cruz García, M. Ferrer Lozano, M. Jesús Alija Merillas, M. Luisa Martínez-Frías, María L. Martínez Fernández, M. Rocío Jadraque, María Asunción García Pérez, María Montserrat Rodríguez Pedreira, María Pilar Ribate, María Teresa González López, María Teresa Moral Pumarega, Mabel Segovia, Macarena Lizama, Manuel Pombo, Margarita Martínez, Margarita Taberero, María Antonia Ramos, María Ballesta, María Belar, María Jesús Lautre, Marta Cruz, M. Nieves Martínez Guardia, F. Javier Martínez Sarries, Mercedes Artigas, Mercedes Villanueva, Meritxell Torrabias, Miguel del Campo, Miguel Tomás Vila, Miguel Urioste, Mónica Rosello, Nik Kantaputra, Pablo Prieto Matos, Paloma Dorao, Paula Casano, Paula Lalaguna Mallada, Pedro Olivares, Raquel Perez Delgado, Priscila Bernardi, Rafael Camino León, Ramón Cañete, Ramón Gaztañaga, Ramón Velazquez, Ramón Vidal Samahuja, Raquel Sáez Villaverde, Ricardo Gracia, Richard Scott, Rita Valdez, Rosa Arteaga, Rosa Cedeño, Rosario Cazorla, Rosario Marín Iglesias, Rubén Bronberg, Salvador Climent, Santiago Conde Barreiro, Seema Kapoor, Soledad Kleppe, Sonia Santillán, Trinidad García Lopez, Teresa Calvo, Teresa Vendrell, Pilar Tirado, Claudia Toledo Pacheco, Alicia Ureta Huertos, Vanesa Lopez, Vanesa Lotersztejn, Vanesa Méndez, Selma Vázquez Martín, Verónica Seidel, Vicente Albiach, Víctor M. Navas López, Virginia Soler, and Viviana Cosentino.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Lapunzina, P. Risk of Tumorigenesis in Overgrowth Syndromes: A Comprehensive Review. *Am. J. Med. Genet. C Semin. Med. Genet.* **2005**, *137C*, 53–71. [[CrossRef](#)]
2. Luscan, A.; Laurendeau, I.; Malan, V.; Francannet, C.; Odent, S.; Giuliano, F.; Lacombe, D.; Touraine, R.; Vidaud, M.; Pasmant, E.; et al. Mutations in SETD2 Cause a Novel Overgrowth Condition. *J. Med. Genet.* **2014**, *51*, 512–517. [[CrossRef](#)]
3. Chen, M.; Quan, Y.; Duan, G.; Wu, H.; Bai, T.; Wang, Y.; Zhou, S.; Ou, J.; Shen, Y.; Hu, Z.; et al. Mutation Pattern and Genotype-Phenotype Correlations of SETD2 in Neurodevelopmental Disorders. *Eur. J. Med. Genet.* **2021**, *64*, 104200. [[CrossRef](#)]
4. Rabin, R.; Radmanesh, A.; Glass, I.A.; Dobyns, W.B.; Aldinger, K.A.; Shieh, J.T.; Romoser, S.; Bombei, H.; Dowsett, L.; Trapane, P.; et al. Genotype-Phenotype Correlation at Codon 1740 of SETD2. *Am. J. Med. Genet. A* **2020**, *182*, 2037–2048. [[CrossRef](#)]
5. Sun, X.; Wei, J.; Wu, X.; Hu, M.; Wang, L.; Wang, H.; Zhang, Q.; Chen, S.; Huang, Q.; Chen, Z. Identification and Characterization of a Novel Human Histone H3 Lysine 36-Specific Methyltransferase. *J. Biol. Chem.* **2005**, *280*, 35261–35271. [[CrossRef](#)]
6. Carvalho, S.; Vítor, A.C.; Sridhara, S.C.; Martins, F.B.; Raposo, A.C.; Desterro, J.M.P.; Ferreira, J.; de Almeida, S.F. SETD2 is Required for DNA Double-Strand Break Repair and Activation of the p53-Mediated Checkpoint. *eLife* **2014**, *3*, e02482. [[CrossRef](#)]
7. Park, I.Y.; Powell, R.T.; Tripathi, D.N.; Dere, R.; Ho, T.H.; Blasius, T.L.; Chiang, Y.; Davis, I.J.; Fahey, C.C.; Hacker, K.E.; et al. Dual Chromatin and Cytoskeletal Remodeling by SETD2. *Cell* **2016**, *166*, 950–962. [[CrossRef](#)]
8. Tenorio, J.; Alarcón, P.; Arias, P.; Dapía, I.; García-Miñaur, S.; Palomares Bralo, M.; Campistol, J.; Climent, S.; Valenzuela, I.; Ramos, S.; et al. Further Delineation of Neuropsychiatric Findings in Tatton-Brown-Rahman Syndrome due to Disease-Causing Variants in DNMT3A: Seven New Patients. *Eur. J. Hum. Genet.* **2020**, *28*, 469–479. [[CrossRef](#)]
9. Tenorio, J.; Alarcón, P.; Arias, P.; Ramos, F.J.; Campistol, J.; Climent, S.; García-Miñaur, S.; Dapía, I.; Hernández, A.; Nevado, J.; et al. MRX93 Syndrome (BRWD3 Gene): Five New Patients with Novel Mutations. *Clin. Genet.* **2019**, *95*, 726–731. [[CrossRef](#)]
10. Newbold, R.F.; Mokbel, K. Evidence for a Tumour Suppressor Function of SETD2 in Human Breast Cancer: A New Hypothesis. *Anticancer Res.* **2010**, *30*, 3309–3311.

11. Kanu, N.; Grönroos, E.; Martinez, P.; Burrell, R.A.; Yi Goh, X.; Bartkova, J.; Maya-Mendoza, A.; Mistrík, M.; Rowan, A.J.; Patel, H.; et al. SETD2 Loss-of-Function Promotes Renal Cancer Branched Evolution through Replication Stress and Impaired DNA Repair. *Oncogene* **2015**, *34*, 5699–5708. [[CrossRef](#)]
12. Skucha, A.; Ebner, J.; Grebien, F. Roles of SETD2 in Leukemia-Transcription, DNA-Damage, and Beyond. *Int. J. Mol. Sci.* **2019**, *20*, 1029. [[CrossRef](#)]
13. O’Roak, B.J.; Vives, L.; Fu, W.; Egertson, J.D.; Stanaway, I.B.; Phelps, I.G.; Carvill, G.; Kumar, A.; Lee, C.; Ankenman, K.; et al. Multiplex Targeted Sequencing Identifies Recurrently Mutated Genes in Autism Spectrum Disorders. *Science* **2012**, *338*, 1619–1622. [[CrossRef](#)]
14. O’Roak, B.J.; Vives, L.; Girirajan, S.; Karakoc, E.; Krumm, N.; Coe, B.P.; Levy, R.; Ko, A.; Lee, C.; Smith, J.D.; et al. Sporadic Autism Exomes Reveal a Highly Interconnected Protein Network of De Novo Mutations. *Nature* **2012**, *485*, 246–250. [[CrossRef](#)]
15. Lumish, H.S.; Wynn, J.; Devinsky, O.; Chung, W.K. Brief Report: SETD2 Mutation in a Child with Autism, Intellectual Disabilities and Epilepsy. *J. Autism Dev. Disord.* **2015**, *45*, 3764–3770. [[CrossRef](#)]
16. Sobreira, N.; Schiettecatte, F.; Valle, D.; Hamosh, A. GeneMatcher: A Matching Tool for Connecting Investigators with an Interest in the Same Gene. *Hum. Mutat.* **2015**, *36*, 928–930. [[CrossRef](#)]
17. Richards, S.; Aziz, N.; Bale, S.; Bick, D.; Das, S.; Gastier-Foster, J.; Grody, W.W.; Hegde, M.; Lyon, E.; Spector, E.; et al. Standards and Guidelines for the Interpretation of Sequence Variants: A Joint Consensus Recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. *Genet. Med.* **2015**, *17*, 405–424. [[CrossRef](#)]
18. Jumper, J.; Evans, R.; Pritzel, A.; Green, T.; Figurnov, M.; Ronneberger, O.; Tunyasuvunakool, K.; Bates, R.; Židek, A.; Potapenko, A.; et al. Highly Accurate Protein Structure Prediction with AlphaFold. *Nature* **2021**, *596*, 583–589. [[CrossRef](#)]
19. Varadi, M.; Anyango, S.; Deshpande, M.; Nair, S.; Natassia, C.; Yordanova, G.; Yuan, D.; Stroe, O.; Wood, G.; Laydon, A.; et al. AlphaFold Protein Structure Database: Massively Expanding the Structural Coverage of Protein-Sequence Space with High-Accuracy Models. *Nucleic Acids Res.* **2022**, *50*, D439–D444. [[CrossRef](#)]
20. Goddard, T.D.; Huang, C.C.; Meng, E.C.; Pettersen, E.F.; Couch, G.S.; Morris, J.H.; Ferrin, T.E. UCSF ChimeraX: Meeting Modern Challenges in Visualization and Analysis. *Protein Sci.* **2018**, *27*, 14–25. [[CrossRef](#)]
21. Pettersen, E.F.; Goddard, T.D.; Huang, C.C.; Meng, E.C.; Couch, G.S.; Croll, T.I.; Morris, J.H.; Ferrin, T.E. UCSF ChimeraX: Structure Visualization for Researchers, Educators, and Developers. *Protein Sci.* **2021**, *30*, 70–82. [[CrossRef](#)]
22. Tlemsani, C.; Luscan, A.; Leulliot, N.; Bieth, E.; Afenjar, A.; Baujat, G.; Doco-Fenzy, M.; Goldenberg, A.; Lacombe, D.; Lambert, L.; et al. SETD2 and DNMT3A Screen in the Sotos-Like Syndrome French Cohort. *J. Med. Genet.* **2016**, *53*, 743–751. [[CrossRef](#)]
23. van Rij, M.C.; Hollink, I.H.I.M.; Terhal, P.A.; Kant, S.G.; Ruivenkamp, C.; van Haeringen, A.; Kievit, J.A.; van Belzen, M.J. Two Novel Cases Expanding the Phenotype of SETD2-Related Overgrowth Syndrome. *Am. J. Med. Genet. A* **2018**, *176*, 1212–1215. [[CrossRef](#)]
24. Marzin, P.; Rondeau, S.; Aldinger, K.A.; Alessandri, J.; Isidor, B.; Heron, D.; Keren, B.; Dobyns, W.B.; Cormier-Daire, V. SETD2 Related Overgrowth Syndrome: Presentation of Four New Patients and Review of the Literature. *Am. J. Med. Genet. C Semin. Med. Genet.* **2019**, *181*, 509–518. [[CrossRef](#)]
25. Suda, K.; Fukuoka, H.; Iguchi, G.; Kanie, K.; Fujita, Y.; Otake, Y.; Matsumoto, R.; Bando, H.; Ito, H.; Takahashi, M.; et al. A Case of Luscan-Lumish Syndrome: Possible Involvement of Enhanced GH Signaling. *J. Clin. Endocrinol. Metab.* **2021**, *106*, 718–723. [[CrossRef](#)]
26. Wu, Y.; Liu, F.; Wan, R.; Jiao, B. A Novel SETD2 Variant Causing Global Development Delay without Overgrowth in a Chinese 3-Year-Old Boy. *Front. Genet.* **2023**, *14*, 1153284. [[CrossRef](#)]
27. Xu, L.; Zheng, Y.; Li, X.; Wang, A.; Huo, D.; Li, Q.; Wang, S.; Luo, Z.; Liu, Y.; Xu, F.; et al. Abnormal Neocortex Arealization and Sotos-Like Syndrome-associated Behavior in Setd2 Mutant Mice. *Sci. Adv.* **2021**, *7*, eaba1180. [[CrossRef](#)]
28. Xie, X.; Wang, S.; Li, M.; Diao, L.; Pan, X.; Chen, J.; Zou, W.; Zhang, X.; Feng, W.; Bao, L. A-TubK40me3 is Required for Neuronal Polarization and Migration by Promoting Microtubule Formation. *Nat. Commun.* **2021**, *12*, 4113. [[CrossRef](#)]
29. Sánchez-Hernández, L.; Hernández-Soto, J.; Vergara, P.; González, R.O.; Segovia, J. Additive Effects of the Combined Expression of Soluble Forms of GAS1 and PTEN Inhibiting Glioblastoma Growth. *Gene Ther.* **2018**, *25*, 439–449. [[CrossRef](#)]

Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.